Company Overview - Deshi Bio is a medical device company focused on developing medical imaging products and services, with a diverse product portfolio aimed at enhancing diagnostic efficiency and service quality [3][5] - The core product, AI AutoVision, is designed for chromosome karyotype analysis, providing timely notifications to doctors regarding chromosomal abnormalities [3][5] Product Pipeline - The company has developed six medical imaging software products, three commercialized medical devices, and four main reagents and consumables [3][5] - AI AutoVision has achieved 100% sensitivity and specificity in detecting numerical abnormalities and 94.05% sensitivity with 100% specificity for structural abnormalities [3][5] Financial Performance - For the fiscal year 2023, the company reported revenues of approximately RMB 52.84 million, with a gross profit of RMB 37.49 million [6][9] - The company recorded a net loss of RMB 56.12 million for the fiscal year 2023 [8] Market Overview - The global smart medical imaging detection market is projected to grow from USD 400 million in 2019 to USD 1.6 billion by 2024, with a compound annual growth rate (CAGR) of 34.6% [10] - In China, the market is expected to expand from RMB 100 million in 2019 to RMB 2.4 billion by 2024, with a CAGR of 80.3% [13] Board of Directors - The board consists of eight members, including two executive directors, three non-executive directors, and three independent non-executive directors, responsible for managing and operating the group's business [16]
德适生物再度递表港交所 专注于开发医学影像产品及服务的医疗器械
Zhi Tong Cai Jing·2026-01-06 23:22